HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

terameprocol

Subscribe to New Research on terameprocol

inhibits HIV Tat-regulated transactivation; structure in first source

Also Known As:

4,4'-(2,3-dimethyl-1,4-butanediyl)bis-1,2-dimethoxybenzene; FW 358.2; FW-358.2; TMNDGA; tetra-O-methyl-NDGA; tetra-O-methylnordihydroguaiaretic acid; tetramethoxynordihydroguaiaretic acid

Networked: 12 relevant articles (0 outcomes, 6 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 58
- Hydrocarbons: 412
  - Cyclic Hydrocarbons: 3
    - Aromatic Hydrocarbons: 132
      - Benzene Derivatives: 13
        Benzyl Compounds: 1
        Lignans: 375
        Nordihydroguaiaretic Acid: 179
        terameprocol: 12
- Phenols: 309
  - Catechols: 85
    - Nordihydroguaiaretic Acid: 179
      - terameprocol: 12

Experts

1.	Bassett, D: 1 article (04/2015)
2.	Hagelstrom, R T: 1 article (04/2015)
3.	Shea, T C: 1 article (04/2015)
4.	McDonagh, K T: 1 article (04/2015)
5.	Tibes, R: 1 article (04/2015)
6.	Frazer, N: 1 article (04/2015)
7.	Garcia, R: 1 article (04/2015)
8.	Schroeder, K: 1 article (04/2015)
9.	Von Hoff, D: 1 article (04/2015)
10.	Beaudry, C: 1 article (04/2015)

Related Diseases

1.	Neoplasms (Cancer) 11/15/2013 - "The semi-synthetic lignan terameprocol inhibits the transcription of several inflammatory and oncogenic genes and has been evaluated for its anti-cancer properties. " 08/15/2009 - "The analogs were evaluated for cytotoxicity in four cancer cell lines and compared to NDGA and tetra-O-methyl-NDGA (M4N) (1a). " 03/01/2008 - "In a phase I clinical trial in patients (25 evaluable) with solid tumors administered intravenous terameprocol, 8 patients exhibited stable disease and 17 had progressive disease; the drug was generally well tolerated. " 03/01/2008 - "Terameprocol, a novel, semisynthetic derivative of a naturally occurring plant lignan, is under development by Erimos Pharmaceuticals LLC for the potential treatment of cancer. " 09/01/2007 - "The terameprocol CPE formulation showed no overt toxicities in tumor-bearing mice. "
2.	Glioma (Gliomas) 04/01/2012 - "Phase I study of terameprocol in patients with recurrent high-grade glioma." 03/01/2008 - "At the time of publication, terameprocol was in phase I or I/II clinical development for the treatment of glioma, treatment-refractory solid tumors and cervical dysplasia; a phase I clinical trial was also planned in patients with hematological cancers. " 04/01/2012 - "The long-term stability noted in some patients and the lack of associated myelosuppression suggest that terameprocol could be safely combined with radiation and temozolomide in newly diagnosed high-grade gliomas."
3.	Cervical Intraepithelial Neoplasia 12/01/2007 - "Terameprocol in 1% and 2% vaginal ointment use in Phase I/II trials with women with HPV-linked cervical intraepithelial neoplasia has an excellent safety profile, no SAEs reported and mild, self-limiting treatment-related AEs. "
4.	Lung Neoplasms (Lung Cancer) 01/01/2011 - "This study examined the effects of terameprocol administration on survivin transcription and expression in HCC2429 and H460 lung cancer cells. " 01/01/2011 - "Further study is warranted to assess the potential of terameprocol as an agent that may enhance the therapeutic ratio of radiotherapy in lung cancer."
5.	Leukemia 04/01/2015 - "Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias." 04/01/2015 - "Terameprocol can be safely administered to advanced leukemia patients, sufficient drug exposure was obtained and clinical activity and biomarker modulation were observed."

Related Drugs and Biologics

1.	terameprocol
2.	Thymidine Monophosphate (TMP)
3.	Polyethylene Glycols (Polyethylene Glycol)
4.	Dimethyl Sulfoxide (DMSO)
5.	2-hydroxypropyl-beta-cyclodextrin
6.	Nordihydroguaiaretic Acid (Masoprocol)
7.	Succinic Acid (Succinate)
8.	Thrombomodulin
9.	Paclitaxel (Taxol)
10.	Mesna (Coenzyme M)

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Radiotherapy
3.	Stents
4.	Intravaginal Administration